Close Menu

UCSD

RADx-UP is funding multiple efforts to determine how marginalized groups, such as undocumented immigrants and those in rural areas, can access testing.

The financing round brings the total amount of funding for Micronoma, a developer of microbiome-based cancer detection technology, to $6.5 million.

The company has developed an analyzer to run PCR, immunochemistry, and cytometry tests at the same time for a variety of diseases including COVID-19.

The test is based on 13 genes that form a gene signature in the blood of children with Kawasaki disease, and it enables KD to be distinguished from other diseases.

The University of California, San Diego spinout is developing a technology that uses microbial DNA signatures for the early detection of cancer.

TargetCancer is activating two enrollment sites and setting up a remote consenting process so patients with rare cancers can be seen at local community hospitals.

Zeesan's test may be used by any CLIA-certified high-complexity lab, while UCSD's test, which uses pooled samples, must be performed by the university.

Irvine, California-based Fluxergy is working with the MGB Center for COVID Innovation to evaluate the firm's research-use-only COVID-19 testing platform.

The effort aims to screen for SARS-CoV-2 in the San Diego community and study the virus' genome to better understand how it is transmitted.

Researchers re-examined whole-genome and whole-transcriptome sequencing TCGA studies from 33 cancer types and found unique microbial signatures.

Pages